These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 21517658

  • 1. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B.
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [Abstract] [Full Text] [Related]

  • 2. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E, Sesti G.
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [Abstract] [Full Text] [Related]

  • 3. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
    Drab SR.
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
    [Abstract] [Full Text] [Related]

  • 4. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 5. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
    Gross B.
    J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
    [Abstract] [Full Text] [Related]

  • 6. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G.
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [Abstract] [Full Text] [Related]

  • 7. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [Abstract] [Full Text] [Related]

  • 8. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Apr; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 9. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J.
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [Abstract] [Full Text] [Related]

  • 10. Liraglutide: clinical pharmacology and considerations for therapy.
    Sisson EM.
    Pharmacotherapy; 2011 Sep; 31(9):896-911. PubMed ID: 21923591
    [Abstract] [Full Text] [Related]

  • 11. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L, Montanya E.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [Abstract] [Full Text] [Related]

  • 12. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

  • 13. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS.
    Postgrad Med; 2011 Jan 10; 123(1):53-65. PubMed ID: 21293084
    [Abstract] [Full Text] [Related]

  • 14. Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies.
    McGill JB.
    Postgrad Med; 2009 May 10; 121(3):16-25. PubMed ID: 19491536
    [Abstract] [Full Text] [Related]

  • 15. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ, Hardy Y.
    J Clin Pharm Ther; 2011 Jun 10; 36(3):260-74. PubMed ID: 21545609
    [Abstract] [Full Text] [Related]

  • 16. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B.
    Diabetes Res Clin Pract; 2012 Jul 10; 97(1):27-42. PubMed ID: 22245694
    [Abstract] [Full Text] [Related]

  • 17. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb 10; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 18. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov 10; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 19. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T.
    Drugs Today (Barc); 2009 Feb 10; 45(2):101-13. PubMed ID: 19343230
    [Abstract] [Full Text] [Related]

  • 20. GLP-1 for type 2 diabetes.
    Ahrén B.
    Exp Cell Res; 2011 May 15; 317(9):1239-45. PubMed ID: 21237153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.